Global Apixaban Market Size, Share, Growth Analysis Report - Forecast 2034
Apixaban Market By Dosage Form (Capsule, Tablets), By End-Users (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others), and By Region: Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034
Category: Pharmaceutical Report Format : PDF
Pages: 204 Report Code: ZMR-4983
Published Date: Jun-2025 Status : Published
| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 2.93 Billion | USD 7.05 Billion | 9.2% | 2024 |
Table Of Content
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Apixaban Market, (2023 - 2030) (USD Billion)
- 2.2 Global Apixaban Market : snapshot
- Chapter 3. Global Apixaban Market - Industry Analysis
- 3.1 Apixaban Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Growing incidences of venous thromboembolism-related ailments will steer the global market trends
- 3.3 Market Restraints
- 3.3.1. Adverse drug effects on patients can put brakes on the global industry surge by 2030
- 3.4 Market Opportunities
- 3.4.1. Huge government investments in healthcare industry will open new growth avenues for the global market over 2023-2030
- 3.5 Market Challenges
- 3.5.1. Low access to proper drug treatment in emerging economies can be a key challenge for the industry across the globe
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Dosage Form
- 3.7.2 Market attractiveness analysis By End-User
- Chapter 4. Global Apixaban Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Apixaban Market: company market share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Apixaban Market - Dosage Form Analysis
- 5.1 Global Apixaban Market overview: By Dosage Form
- 5.1.1 Global Apixaban Market share, By Dosage Form, 2022 and 2030
- 5.2 Capsule
- 5.2.1 Global Apixaban Market by Capsule, 2023 - 2030 (USD Billion)
- 5.3 Tablet
- 5.3.1 Global Apixaban Market by Tablet, 2023 - 2030 (USD Billion)
- 5.1 Global Apixaban Market overview: By Dosage Form
- Chapter 6. Global Apixaban Market - End-User Analysis
- 6.1 Global Apixaban Market overview: By End-User
- 6.1.1 Global Apixaban Market share, By End-User, 2022 and 2030
- 6.2 Hospitals
- 6.2.1 Global Apixaban Market by Hospitals, 2023 - 2030 (USD Billion)
- 6.3 Clinics
- 6.3.1 Global Apixaban Market by Clinics, 2023 - 2030 (USD Billion)
- 6.4 Retail Pharmacies
- 6.4.1 Global Apixaban Market by Retail Pharmacies, 2023 - 2030 (USD Billion)
- 6.5 Online Pharmacies
- 6.5.1 Global Apixaban Market by Online Pharmacies, 2023 - 2030 (USD Billion)
- 6.6 Others
- 6.6.1 Global Apixaban Market by Others, 2023 - 2030 (USD Billion)
- 6.1 Global Apixaban Market overview: By End-User
- Chapter 7. Apixaban Market - Regional Analysis
- 7.1 Global Apixaban Market Regional Overview
- 7.2 Global Apixaban Market Share, by Region, 2022 & 2030 (USD Billion)
- 7.3. North America
- 7.3.1 North America Apixaban Market, 2023 - 2030 (USD Billion)
- 7.3.1.1 North America Apixaban Market, by Country, 2023 - 2030 (USD Billion)
- 7.3.1 North America Apixaban Market, 2023 - 2030 (USD Billion)
- 7.4 North America Apixaban Market, by Dosage Form, 2023 - 2030
- 7.4.1 North America Apixaban Market, by Dosage Form, 2023 - 2030 (USD Billion)
- 7.5 North America Apixaban Market, by End-User, 2023 - 2030
- 7.5.1 North America Apixaban Market, by End-User, 2023 - 2030 (USD Billion)
- 7.4. Europe
- 7.4.2 Europe Apixaban Market, 2023 - 2030 (USD Billion)
- 7.4.2.1 Europe Apixaban Market, by Country, 2023 - 2030 (USD Billion)
- 7.4.2 Europe Apixaban Market, 2023 - 2030 (USD Billion)
- 7.4 Europe Apixaban Market, by Dosage Form, 2023 - 2030
- 7.4.1 Europe Apixaban Market, by Dosage Form, 2023 - 2030 (USD Billion)
- 7.5 Europe Apixaban Market, by End-User, 2023 - 2030
- 7.5.1 Europe Apixaban Market, by End-User, 2023 - 2030 (USD Billion)
- 7.5. Asia Pacific
- 7.5.3 Asia Pacific Apixaban Market, 2023 - 2030 (USD Billion)
- 7.5.3.1 Asia Pacific Apixaban Market, by Country, 2023 - 2030 (USD Billion)
- 7.5.3 Asia Pacific Apixaban Market, 2023 - 2030 (USD Billion)
- 7.4 Asia Pacific Apixaban Market, by Dosage Form, 2023 - 2030
- 7.4.1 Asia Pacific Apixaban Market, by Dosage Form, 2023 - 2030 (USD Billion)
- 7.5 Asia Pacific Apixaban Market, by End-User, 2023 - 2030
- 7.5.1 Asia Pacific Apixaban Market, by End-User, 2023 - 2030 (USD Billion)
- 7.6. Latin America
- 7.6.4 Latin America Apixaban Market, 2023 - 2030 (USD Billion)
- 7.6.4.1 Latin America Apixaban Market, by Country, 2023 - 2030 (USD Billion)
- 7.6.4 Latin America Apixaban Market, 2023 - 2030 (USD Billion)
- 7.4 Latin America Apixaban Market, by Dosage Form, 2023 - 2030
- 7.4.1 Latin America Apixaban Market, by Dosage Form, 2023 - 2030 (USD Billion)
- 7.5 Latin America Apixaban Market, by End-User, 2023 - 2030
- 7.5.1 Latin America Apixaban Market, by End-User, 2023 - 2030 (USD Billion)
- 7.7. The Middle-East and Africa
- 7.7.5 The Middle-East and Africa Apixaban Market, 2023 - 2030 (USD Billion)
- 7.7.5.1 The Middle-East and Africa Apixaban Market, by Country, 2023 - 2030 (USD Billion)
- 7.7.5 The Middle-East and Africa Apixaban Market, 2023 - 2030 (USD Billion)
- 7.4 The Middle-East and Africa Apixaban Market, by Dosage Form, 2023 - 2030
- 7.4.1 The Middle-East and Africa Apixaban Market, by Dosage Form, 2023 - 2030 (USD Billion)
- 7.5 The Middle-East and Africa Apixaban Market, by End-User, 2023 - 2030
- 7.5.1 The Middle-East and Africa Apixaban Market, by End-User, 2023 - 2030 (USD Billion)
- Chapter 8. Company Profiles
- 8.1 F. Hoffmann-La Roche Ltd
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 Hikma Pharmaceuticals PLC
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 Eisai Co. Ltd
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 Sanofi S.A.
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Yino Pharma Limited
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Mylan N.V.
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 Bristol Myers Squibb Company
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 Abbott Laboratories
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 Hebei Changshan Biochemical Pharmaceutical Co. Ltd
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.10 Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
- 8.10.1 Overview
- 8.10.2 Financials
- 8.10.3 Product Portfolio
- 8.10.4 Business Strategy
- 8.10.5 Recent Developments
- 8.11 Aspen Holdings
- 8.11.1 Overview
- 8.11.2 Financials
- 8.11.3 Product Portfolio
- 8.11.4 Business Strategy
- 8.11.5 Recent Developments
- 8.12 Fresenius Kabi AG
- 8.12.1 Overview
- 8.12.2 Financials
- 8.12.3 Product Portfolio
- 8.12.4 Business Strategy
- 8.12.5 Recent Developments
- 8.13 Pfizer Inc.
- 8.13.1 Overview
- 8.13.2 Financials
- 8.13.3 Product Portfolio
- 8.13.4 Business Strategy
- 8.13.5 Recent Developments
- 8.14 and others.
- 8.14.1 Overview
- 8.14.2 Financials
- 8.14.3 Product Portfolio
- 8.14.4 Business Strategy
- 8.14.5 Recent Developments
- 8.1 F. Hoffmann-La Roche Ltd
Table Of Figures
- 1. Market research Type
- 2. Market research methodology
- 3. Global Apixaban Market, 2023 - 2030 (USD Billion)
- 4. Porter’s Five Forces Analysis
- 5. Global Apixaban Market attractiveness, By Dosage Form
- 6. Global Apixaban Market attractiveness, By End-User
- 7. Global Apixaban Market share by Dosage Form, 2023 and 2030 (USD Billion)
- 8. Global Apixaban Market by Capsule, 2023 - 2030 (USD Billion)
- 9. Global Apixaban Market by Tablet, 2023 - 2030 (USD Billion)
- 10. Global Apixaban Market share by End-User, 2023 and 2030 (USD Billion)
- 11. Global Apixaban Market by Hospitals, 2023 - 2030 (USD Billion)
- 12. Global Apixaban Market by Clinics, 2023 - 2030 (USD Billion)
- 13. Global Apixaban Market by Retail Pharmacies, 2023 - 2030 (USD Billion)
- 14. Global Apixaban Market by Online Pharmacies, 2023 - 2030 (USD Billion)
- 15. Global Apixaban Market by Others, 2023 - 2030 (USD Billion)
- 16. Global Apixaban Market share, by Region, 2023 and 2030
- 17. North America Apixaban Market, 2023 - 2030 (USD Billion)
- 18. Europe Apixaban Market, 2023 - 2030 (USD Billion)
- 19. Asia Pacific Apixaban Market, 2023 - 2030 (USD Billion)
- 20. Latin America Apixaban Market, 2023 - 2030 (USD Billion)
- 21. The Middle-East and Africa Apixaban Market, 2023 - 2030 (USD Billion)
Table Of Tables
- 1. Global Apixaban Market: Snapshot
- 2. Drivers of the Apixaban Market: impact analysis
- 3. North America Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 4. North America Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 5. U.S. Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 6. U.S. Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 7. Canada Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 8. Canada Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 9. Europe Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 10. Europe Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 11. Germany Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 12. Germany Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 13. France Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 14. France Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 15. U.K. Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 16. U.K. Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 17. Italy Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 18. Italy Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 19. Spain Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 20. Spain Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 21. Rest of Europe Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 22. Rest of Europe Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 23. Asia Pacific Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 24. Asia Pacific Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 25. China Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 26. China Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 27. Japan Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 28. Japan Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 29. India Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 30. India Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 31. South Korea Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 32. South Korea Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 33. South-East Asia Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 34. South-East Asia Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 35. Rest of Asia Pacific Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 36. Rest of Asia Pacific Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 37. Latin America Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 38. Latin America Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 39. Brazil Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 40. Brazil Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 41. Mexico Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 42. Mexico Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 43. Rest of Latin America Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 44. Rest of Latin America Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 45. The Middle-East and Africa Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 46. The Middle-East and Africa Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 47. GCC Countries Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 48. GCC Countries Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 49. South Africa Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 50. South Africa Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
- 51. Rest of Middle-East Africa Apixaban Market revenue, By Dosage Form, 2023 - 2030 (USD Billion)
- 52. Rest of Middle-East Africa Apixaban Market revenue, By End-User, 2023 - 2030 (USD Billion)
Methodology
FrequentlyAsked Questions
Factor Xa is a serine protease-like trypsin that plays an important role in the cascade of blood coagulation. Apixaban mechanism works on Xa factor inhibiting which indirectly decreases thrombin-stimulated clot formation. Precisely, apixaban is an anticoagulant medicine utilized for treating and preventing blood clots & heart strokes in patients. In addition to this, Apixaban is recommended in patients with non-valvular atrial fibrillation to reduce the risk of stroke or systemic embolism.
The global apixaban market is expected to grow due to increasing prevalence of cardiovascular diseases, the growing geriatric population, Apixaban's favorable safety and efficacy profile compared to traditional anticoagulants, and the rising demand for novel oral anticoagulants (NOACs) due to their convenien.
According to a study, the global apixaban market size was worth around USD 2.93 Billion in 2024 and is expected to reach USD 7.05 Billion by 2034.
The global apixaban market is expected to grow at a CAGR of 9.2% during the forecast period.
North America is expected to dominate the apixaban market over the forecast period.
Leading players in the global apixaban market include F. Hoffmann-La Roche Ltd. (Switzerland), Mylan NV (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GSK plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Lilly (US), Amgen Inc. (US), Eisai Co., Ltd (Japan), Aspen Holdings (South Africa), Fresenius Kabi AG (Germany), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), OPOCRIN SPA (Italy), SARIA International GmbH (Germany), Hepalink Group (China)., Shenzhen Techdow Pharmaceutical Co., Ltd (China), Yino Pharma Limited (China), among others.
The report explores crucial aspects of the apixaban market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients
